Cancer Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Anal Cancer
Shorter irradiation and added mitomycin C are now standard EORTC therapy
April 22nd, 2003
A new, more effective EORTC protocol for treatment of anal cancer involves addition of mitomycin C. According to recent research from France, "The European Organization for Research and Treatment of Cancer (EORTC) 22861 randomized trial established that combined radiochemotherapy is the standard treatment for locally advanced anal cancer. "This EORTC phase II study (#22953) tests the feasibility of reducing the gap between sequences to 2 weeks, to deliver mitomycin C (MMC) in each radiotherapy sequence and 5-FU continuously during the treatment. "The first sequence consisted of 36 Gy over 4 weeks, 5-FU 200 mg/m2/days...
Source: Cancer Weekly (2003-04-22)
|
